Roche (VTX:ROG) has been assigned a CHF 237 price objective by analysts at UBS Group in a research report issued to clients and investors on Tuesday, www.boersen-zeitung.de reports. The firm presently has a “neutral” rating on the healthcare company’s stock. UBS Group’s target price suggests a potential upside of 6.80% from the stock’s current price.
Several other analysts also recently weighed in on ROG. Morgan Stanley set a CHF 260 price objective on Roche and gave the stock a “neutral” rating in a research report on Friday, November 17th. Deutsche Bank set a CHF 264 price objective on Roche and gave the stock a “neutral” rating in a research report on Tuesday, December 12th. Liberum Capital set a CHF 279 price objective on Roche and gave the stock a “buy” rating in a research report on Wednesday, November 22nd. Goldman Sachs Group set a CHF 325 price objective on Roche and gave the stock a “buy” rating in a research report on Wednesday, February 7th. Finally, Barclays set a CHF 295 price objective on Roche and gave the stock a “buy” rating in a research report on Monday, February 5th. Four investment analysts have rated the stock with a sell rating, seven have issued a hold rating and ten have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of CHF 256.05.
Shares of Roche (VTX:ROG) opened at CHF 221.90 on Tuesday. The stock has a market capitalization of $192,070.00 and a price-to-earnings ratio of 22.10. Roche has a 1-year low of CHF 214.30 and a 1-year high of CHF 273.
Roche Holding AG (Roche) is a research-based healthcare company. The Company’s operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics.
Receive News & Ratings for Roche Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche and related companies with MarketBeat.com's FREE daily email newsletter.